Table 3.

Univariate analysis of OS, LRC, and PFS

	N	Two‐year OS	SD	P	Two‐year LRC	SD	P	Two‐year PFS	SD	P
Gender
Male	36	56	9	0.123	52	9	0.387	28	8	0.635
Female	8	57	19		75	15		31	18
Age
<60	24	67	10	0.085	58	11	0.896	34	11	0.402
≥60	20	43	11		54	11		23	10
Clinical T stage
T2/T3	38	51	9	0.334	57	8	0.975	28	8	0.900
T4	6	67	20		50	20		33	19
Clinical N stage
N0	13	63	15	0.693	75	13	0.161	57	15	0.118
N+	31	53	9		49	9		18	7
Clinical stage grouping
II	13	54	15	0.754	49	15	0.413	40	15	0.608
III	31	56	9		60	9		25	8
Grading
Grade 1	13	59	14	0.093	73	14	0.292	48	16	0.176
Grade 2	18	50	13		45	12		13	9
Grade 3	4	75	22		50	25		50	25
Unknown	9	56	17		56	17		22	14
Location
Upper/mid	23	61	10	0.902	52	11	0.581	34	10	0.697
Lower	21	51	12		62	12		24	10
Length
≤8 cm	32	56	9	0.316	53	9	0.657	18	7	0.068
>8 cm	12	56	15		67	14		57	15
Weight loss
<10%	28	50	10	0.268	51	10	0.543	16	7	0.065
≥10%	16	67	12		66	13		53	13
Dose
>5000–6000	22	35	12	0.026	41	12	0.104	18	10	0.143
>6000	22	73	10		68	10		36	10
Resection margin
R0	31	71	9	0.002*	61	9	0.277	36	9	0.021
R1–R2	13	21	12		45	14		10	9
Pathologic staging
pCR	21	71	11	0.055	78	10	0.031	50	12	0.002*
non pCR	23	44	10		39	10		13	7

^*Factors with P < 0.004 (adjusted P value for multiple comparison).

LRC, locoregional control; OS, overall survival; pCR, pathologic complete response; PFS, progression‐free survival; SD, standard deviation.